Author:
Roider Elisabeth,Lakatos Alexandra I. T.,McConnell Alicia M.,Wang Poguang,Mueller Alina,Kawakami Akinori,Tsoi Jennifer,Szabolcs Botond L.,Ascsillán Anna A.,Suita Yusuke,Igras Vivien,Lo Jennifer A.,Hsiao Jennifer J.,Lapides Rebecca,Pál Dorottya M. P.,Lengyel Anna S.,Navarini Alexander,Okazaki Arimichi,Iliopoulos Othon,Németh István,Graeber Thomas G.,Zon Leonard,Giese Roger W.,Kemeny Lajos V.,Fisher David E.
Abstract
AbstractMicrophthalmia-associated transcription factor (MITF) is a master regulator of melanocyte function, development and plays a significant role in melanoma pathogenesis. MITF genomic amplification promotes melanoma development, and it can facilitate resistance to multiple therapies. Here, we show that MITF regulates a global antioxidant program that increases survival of melanoma cell lines by protecting the cells from reactive oxygen species (ROS)-induced damage. In addition, this redox program is correlated with MITF expression in human melanoma cell lines and patient-derived melanoma samples. Using a zebrafish melanoma model, we show that MITF decreases ROS-mediated DNA damage in vivo. Some of the MITF target genes involved, such as IDH1 and NNT, are regulated through direct MITF binding to canonical enhancer box (E-BOX) sequences proximal to their promoters. Utilizing functional experiments, we demonstrate the role of MITF and its target genes in reducing cytosolic and mitochondrial ROS. Collectively, our data identify MITF as a significant driver of the cellular antioxidant state.
Funder
Mildred Scheel Grant of the German Cancer Society and the Filling the Gap grant of the University of Zurich, Switzerland
Filling the Gap grant of the University of Zurich
NIH
Melanoma Research Alliance
János Bolyai Research Scholarship of the Hungarian Academy of Sciences
Development and Innovation Office
KIM NKFIA
KIM
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Publisher
Springer Science and Business Media LLC